Bristol-myers Squibb Stock News

Leukemia Therapeutics Market Snapshot: The Global Leukemia Therapeutics Market is expected to grow at a steady growth during the forecast period 2019-2029, Leukemia Therapeutics Market report offers insights into the latest trends. It summarizes key aspects of the market, with a

Grace & White Inc. NY reduced its position in Bristol-Myers Squibb (NYSE:BMY) by 18.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 8,073 shares of the biopharmaceutical companys stock after selling 1,775 shares during the period. Grace & White []

DUBLIN--(BUSINESS WIRE)--The "Immunosuppressants Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com''s offering. The global immunosuppressants market is expected to grow from $15.04 billion in 2020 to $16.5 billion in 2021 at a compound annual growth rate (CAGR) of 9.7%. The market is expected to reach $25.33 billion in 2025 at a CAGR of 11%. Major players in the immunosuppressant market are Astellas Pharma, GlaxoSmithKline, Bristol Mye

Boenning & Scattergood Inc. lifted its stake in Bristol-Myers Squibb (NYSE:BMY) by 7.2% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 55,253 shares of the biopharmaceutical companys stock after buying an additional 3,721 shares during the period. Boenning & Scattergood []

The Biologics market report presents the global Biologics sales and revenue by companies, regions, type and application and forecast to 2026. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities

6 Dividend Increases Expected In December 2021

The Pharmacovigilance Market report focus on the current trends of the market along with detailed analysis which provides data regarding this market rate, and it also predicts the future market growth rate. The Pharmacovigilance Market study includes research on the

Bristol Myers' (BMY) sBLA seeking label expansion of Reblozyl for the treatment of anemia in adults with non-transfusion dependent (NTD) beta thalassemia gets priority review by the FDA.

These three pharmaceutical stocks could buffer your portfolio against further market turbulence.

Rising quarterly payouts and above-average yields make these dividend stocks worthy of your immediate attention.

Bristol-Myers Squibb has underperformed through 2021. However, the company is continuing to move forward on its targets.

(PR-inside.com) NEW ORLEANS, LA / ACCESSWIRE / December 5, 2021 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until December 6, 2021 to file lead plaintiff applications in securities class action lawsuits against Bristol-Myers Squibb Company ("BMS" or "the Company") (NYSE:BMY), if they received Contingent Value Rights ("CVRs") in exchange for their shares of Celgene Corporation pursuant to BMS'' acquisition of Celgene on November 20, 2019. These actions are pending in the United States District Court for the Southern District of New York. What You ..

Virginia Retirement Systems ET AL raised its stake in Bristol-Myers Squibb (NYSE:BMY) by 0.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,457,700 shares of the biopharmaceutical companys stock after purchasing an additional 4,300 shares during the period. Bristol-Myers Squibb accounts for []

StoneX Group Inc. increased its stake in Bristol-Myers Squibb (NYSE:BMY) by 5.7% during the third quarter, Holdings Channel.com reports. The fund owned 19,526 shares of the biopharmaceutical companys stock after buying an additional 1,052 shares during the period. StoneX Group Inc.s holdings in Bristol-Myers Squibb were worth $1,165,000 at the end of the most recent []

Roche is optimally diversified both in terms of geography and in terms of portfolio. Pfizer and Eli Lilly are also broadly diversified but are more U.S.-centric companies. AbbVie, but also Merck are c